Evidence map›Paper›PMID 30230263›Full record

Trial reportClinical pharmacology in drug development2018

Pharmacokinetics, Excretion, and Mass Balance of [

Claire Ambery, Graeme Young, Teresa Fuller, Aili L Lazaar, Adrian Pereira, Adam Hughes, David Ramsay, Frans van den Berg, Peter Daley-Yates

Erratum issuedAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical pharmacology in drug development, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Claire AmberyClinical Pharmacology Modelling and Simulation, GSK, Stockley Park West, Uxbridge, Middlesex, UK.
Graeme YoungBioanalysis, Immunogenicity and Biomarkers (BIB), GSK, Ware, Hertfordshire, UK.
Teresa FullerGSK, Medicines Research Centre, Stevenage, Hertfordshire, UK.
Aili L LazaarRespiratory Therapy Area Unit, GSK, R&D, King of Prussia, PA, USA.
Adrian PereiraBioanalysis, Immunogenicity and Biomarkers (BIB), GSK, Ware, Hertfordshire, UK.
Adam HughesBioanalysis, Immunogenicity and Biomarkers (BIB), GSK, Ware, Hertfordshire, UK.
David RamsayQuanticate Ltd., Edinburgh, UK.
Frans van den BergHammersmith Medicines Research, London, UK.
Peter Daley-YatesClinical Development, GSK, Research and Development, Uxbridge, Middlesex, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inhaled batefenterol is an investigational bifunctional molecule for the treatment of chronic obstructive pulmonary disease. The excretion balance and pharmacokinetics of batefenterol using [

Indexed as

Administration, InhalationAdministration, IntravenousAdministration, OralAdultBiological AvailabilityBronchodilator AgentsCarbamatesCarbon RadioisotopesCross-Over StudiesFecesHealthy VolunteersHumansMaleMiddle AgedQuinolonesbatefenterolBronchodilator AgentsCarbamatesCarbon RadioisotopesQuinolonesbatefenterolchiral inversionmicrotracerpharmacokinetics

Identifiers

PMID30230263
PMCPMC6282586

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.